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The Antenatal Genetic Testing Program at 
MCV began in 1973. The standard scheme for 
antenatal genetic testing involves counseling. 
the methods of carrier detection available, ul­
trasound, amniocentesis, and laboratory evalu­
ation. Patients are referred because of a family 
or personal history of a genetic abnormality or 
because they have been evaluated in a carrier 
detection program like those for Tay-Sachs dis­
ease or Sickle Cell disease and are known car­
riers. After referral, patients are given genetic 
counseling by me and members of the Depart­
ment of Human Genetics; if antenatal genetic 
testing is deemed appropriate, we obtain in­
formed consent and proceed with an ultrasound 
study. The primary reason for doing an ul­
trasound study prior to amniocentesis is to de­
tect twins. Twins are most likely to be in sepa­
rate amniotic sacs and have different 
karyotypes; therefore, fluid must be obtained 
from each sac. 
The indications for referral are listed in 
Table 1. The most frequent is advanced mater­
nal age, generally considered to be 35 years or 
greater. If a mother is less than 35 years and 
pregnant, she has a 0.2% risk of having a child 
with Down Syndrome (about 1 in 600). Between 
35 and 40 years of age the risk of having a 
child with Down Syndrome is between 1 % and 
1 %% and between 40 and 45 years of age it is 
about 2% or about a 5 to 1 0 times greater risk 
than the general population. 
Another common reason for ultrasound 
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study is that the patient has had a previously 
chromosomany abnormal child. The most com­
mon abnormality is Trisomy 21 in which case 
risk of the recurrence is 1 %. Occasionally, we 
find that the proband has a translocation abnor­
mality and that one of the parents is a balanced 
carrier which results in a rate of recurrence of 
from 20% to 1 00%. A significant family history 
of chromosomally abnormal offspring (sister, 
brother. and their children) may also be a clue 
lo a translocation defect. Other indications for 
studies include metabolic defects amenable to 
prenatal detection and a previous child or 
known carrier status for a sex-linked disease 
(hemophilia or Duchenne muscular dystrophy). 
The history of a previous child or close relative 
with a neural tube defect (NTD) (either anence­
phaly, encephalocele or meningomyelocele) is 
a very common reason for referral_ Neural tube 
defects have a genetic component, so that if a 
couple has had an affected child, the risk of a 
subsequent child with a NTD is 5%, and if there 
have been two affected children, the risk is 
10% for having a child with a NTD. Patients 
with close relatives with a NTD have a 1 % risk 
of occurrence. 
As mentioned, ultrasound is used primar­
ily to diagnose twins. Once twins have been 
ruled out ultrasound is very useful for locating a 
pocket of amniotic fluid and measuring the 
angle and depth at which the needle has to en­
ter the sac to withdraw fluid. The Figure is an ul­
trasound visualization of a uterus, with the fetus 
inside, at about 14 weeks gestation. The chest 
and head are easily identified, as is a thick ante­
rior placenta. The amniotic fluid is the dark area 
and the proper needle placement is indicated. 
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TABLE 1 
Indications for Referral for Antenatal Genetic Testing 
I Advanced malernal age (2: 35 years old) 
2 Previous child with a chromosome abnormality 
3 Parents who carry a transtocation gene 
4 Previous child with an inborn error of metabolism 
5 Previous child with a severe X-1,nked disease 
6 Previous child or close retat,ve w,th a neural tube defect 
Amniocentesis is the procedure by which 
amniotic fluid is obtained through the abdomen 
of the mother with a needle. (If we have prob­
lems obtaining fluid we can use ultrasound in 
con1unction with amniocentesis to see the tip of 
the needle ) We use a disposable kit for amnio­
centesis which has a 22-gauge spinal needle, 
local anesthesia, and Betadine swabs, which 
are used to prepare the abdomen after we have 
decided where the needle is to be inserted. Af­
ter draping the abdomen with a sterile towel, the 
skin and subcutaneous tissue is anesthetized 
and the needle is inserted. The needle has a 
stylet which is then removed and an extension 
tube attached without interrupting the flow of 
fluid being withdrawn through the needle. Since 
the most common laboratory evaluation from 
the amniotic fluid is chromosome analysis, the 
fluid is processed by the cytogenetic lab in the 
Department of Human Genetics. It takes three 
to four weeks to complete the analysis with a 
range of about two and one half to six weeks. 
The fetal karyotypes are obtained from cultured 
fetal cells in the amniotic fluid obtained at 1 4 to 
1 6 weeks gestation 
Another fairly recent and exciting area in 
the field of intrauterine diagnosis is that of fetal 
structural defects. The first group successfully 
diagnosed is Neural Tube Defects (NTD) with 
the association of elevated amniotic fluid alpha­
fetoprotein in pregnancies with a NTD. In 1972 
Brock and Sutcliff' published a series of pa: 
TABLE 2 
Results of Antenatal Genetic Testing 
9-1-73 to 9-6-79 
269 46XY (normal mate) 
255 46XX (normal female) 
5 46XX+21 and 46XY+21 (Trisomy 21) 
45XO (Turner syndrome) 
4 ?XX+ 18 (Trisomy 18) 
4 5XY. I ( 1 8p 21 p) 
46XX 46XXr(9) (mosaic) 
45XX, I( 14q,21 q) 
46XX. 45 XO (mosaic) 
46XX. I (6p, l 4p) 
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tients in whom they had measured the amnioti� 
fluid alpha-fetoprotein and found that there was 
clearly a significant difference between a group 
affected with NTD and a normal control group. 
The most accurate range of pregnancy to mea­
sure alpha-fetoprotein is 1 4 to 1 8 weeks. The 
diagnosis of anencephaly and large men­
ingomyeloceles can also be made easily with 
modern ultrasound techniques. Because men­
ingomyeloceles and spina bifida are more diffi­
cult to demonstrate by ultrasound, we rely 
mainly on alpha-fetoprotein in the amniotic fluid 
for their detection. In addition, with more so­
phisticated ultrasound equipment, we are able 
to diagnose other structural defects such as 
dwarfism (by measuring fetal limb lengths) and 
polycystic kidneys (Potter syndrome). 
A number of questions are frequently 
asked about this testing Could you accidentally 
hit the baby with the needle? This has certainly 
happened and has been reported in the litera­
ture. I reviewed one series with an intracardiac 
fetal puncture and death during an amniocen­
tesis at 1 6 weeks. The recorded pregnancy loss 
rate nationwide is about 1 % as a result of am­
niocentesis. At MCV two pregnancies have 
been lost in a series of 531 patients One pa­
tient developed chorioamnionitis within 24 
hours and one patient had ruptured membranes 
about an hour after the procedure, giving a fetal 
mortality of 0.4%. We have had no fetal punc-
F,gure- Ultrasound visualization of a fetus in utero at 1 4 
weeks gestation 
tures. This 1s an acceptable mortality rate con­
sillering that most of these patients have at least 
a i1 % risk of having an abnormality and some 
as high as 5%. 
Another common question is, how much 
does it cost to have the testing?2 The cost var­
ies from center to center, but the range in Vir­
ginia is $4 70 to $520. MCV charges $520 
which includes genetic counseling, amniocen­
tesis, ultrasound study and karyotype examina­
tion. If the patient needs only the alpha-fetopro­
tein determination, the cost is $1 7 5. The MCV 
experience with antenatal genetic studies in­
volves 531 patients, the majority of whom were 
studied because of advanced maternal age. 
The second most common indication was a pre-
v1ous cl11ld with a NTD and the third was a pre­
vious child with Trisomy 21 The rest were a va­
riety of indications; perhaps the most interesting 
was one patient who demanded elective sex de­
termination. The results of chromosome analy­
sis from our patients are presented in Table 2. 
Five fetuses were diagnosed as having Down 
Syndrome, and of seven fetuses with abnormal 
alpha-fetoprotein, all had a NTD. All abnormal 
fetuses were aborted and the diagnosis con­
firmed. 
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